Focus: Aura Biosciences is a Boston-based biotechnology company specializing in pseudo-virus delivery technology for oncology and nephrology indications. The company is in clinical-stage development with a focused pipeline centered on ocular and uveal malignancies.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Aura is a technically differentiated but capital-constrained pre-revenue biotech best suited for scientists seeking deep pipeline involvement in rare oncology, with meaningful execution risk typical of early-stage companies.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aura Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Aura Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
8-K Filing: Aura Biosciences, Inc. (AURA) (CIK 0001501796) — EX-99.1
EX-99.1
Latest AURA News - Aura Biosciences to Participate at the 11th... - Stock Titan
Latest AURA News - Aura Biosciences to Participate at the 11th... Stock Titan
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline - Yahoo Finance
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline Yahoo Finance
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Re: Mattia Longoni, Leonardo Quarta, Donato Cannoletta, et al. Long-term Functional Outcomes and Decision Regret after Robot-assisted Radical Prostatectomy: An Experienced Surgeon Series. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.12.014.
Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2025.11.007.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo